Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gleave

Showing results (111-120 of 259) with videos related to

Pageof 26
Sort By:
European Urology|May 16, 2016
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway InhibitionYinan Li, Nilgun Donmez, Cenk Sahinalp, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 25, 2018
Natural history of prostatic lesions on serial multiparametric magnetic resonance imagingSamrad Ghavimi, Hamidreza Abdi, Jennifer Waterhouse, et al.
Experimental Cell Research|August 23, 2005
Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitroPaulo Ferreira, Maria José Oliveira, Eliana Beraldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate CancerYoshiaki Yamamoto, Paulo J C Lin, Eliana Beraldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancerAlan I So, Randy J Levitt, Bernhard Eigl, et al.
The Journal of Biological Chemistry|June 27, 2013
Mutation of the salt bridge-forming residues in the ETV6-SAM domain interface blocks ETV6-NTRK3-induced cellular transformationNaniye Cetinbas, Helen Huang-Hobbs, Cristina Tognon, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 17, 2010
Comparison of bifunctional chelates for (64)Cu antibody imagingCara L Ferreira, Donald T T Yapp, Sarah Crisp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2013
The mechanism of DAB2IP in chemoresistance of prostate cancer cellsKaijie Wu, Daxing Xie, Yonglong Zou, et al.
EMBO Molecular Medicine|May 21, 2016
Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosisNader Al Nakouzi, Chris Kedong Wang, Eliana Beraldi, et al.
Cold Spring Harbor Molecular Case Studies|September 3, 2017
A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agentsDavid C Wilkes, Verena Sailer, Hui Xue, et al.
Pageof 26

Showing results (111-120 of 259) with videos related to

Sort By:
Pageof 26
European Urology|May 16, 2016
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway InhibitionYinan Li, Nilgun Donmez, Cenk Sahinalp, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 25, 2018
Natural history of prostatic lesions on serial multiparametric magnetic resonance imagingSamrad Ghavimi, Hamidreza Abdi, Jennifer Waterhouse, et al.
Experimental Cell Research|August 23, 2005
Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitroPaulo Ferreira, Maria José Oliveira, Eliana Beraldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate CancerYoshiaki Yamamoto, Paulo J C Lin, Eliana Beraldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancerAlan I So, Randy J Levitt, Bernhard Eigl, et al.
The Journal of Biological Chemistry|June 27, 2013
Mutation of the salt bridge-forming residues in the ETV6-SAM domain interface blocks ETV6-NTRK3-induced cellular transformationNaniye Cetinbas, Helen Huang-Hobbs, Cristina Tognon, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 17, 2010
Comparison of bifunctional chelates for (64)Cu antibody imagingCara L Ferreira, Donald T T Yapp, Sarah Crisp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2013
The mechanism of DAB2IP in chemoresistance of prostate cancer cellsKaijie Wu, Daxing Xie, Yonglong Zou, et al.
EMBO Molecular Medicine|May 21, 2016
Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosisNader Al Nakouzi, Chris Kedong Wang, Eliana Beraldi, et al.
Cold Spring Harbor Molecular Case Studies|September 3, 2017
A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agentsDavid C Wilkes, Verena Sailer, Hui Xue, et al.
Pageof 26